This is a working overview of animal models, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-29. Anything still debated is marked as such rather than presented as settled.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Approximate, for sequence GEPPPGKPADDAGLV |
| Molecular mass | ~1419 Da | Neutral form |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Typical storage | -20 C | Dry powder, protected from moisture |
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Ruthenium has no radioactive isotopes with half-lives much longer than a year and the price of ruthenium is relatively high, making the destruction of 99Tc into a potentially lucrative source of producing a precious metal from an undesirable feedstock.
== Nonclinical toxicology == Sitagliptin: Using male and female rats, a two-year carcinogenicity study was carried out with doses of 50, 150, and 500 mg/kg/day. The 500 mg/kg dose has exposure limits of 60 times what would be seen in the highest dose in humans. At this dose, liver adenoma/carcinoma was seen. Tumors were not seen from the smaller doses. Nomutagenic or clastogenic effects were seen from tests using several assays (CHO, rat, etc.). Fertility studies in rats showed no teratogenic effects. Simvastatin: No tumorigenic effect was seen in a 72-week carcinogenicity study using mice at the low dose levels. However, at the higher dose levels (eight and 16 times the human dose equivalent), liver carcinomas and adenomas, lung adenomas, and adenomas of the Harderian gland occurred. No mutagenic effects were seen in assays. Testicular atrophy was noted in dogs and rats at four and eight times the human exposure, respectively.
=== Amino acid sequence === The linear amino acid sequence of a protein is called the primary structure. The primary structure can be easily determined from the sequence of codons on the DNA gene that codes for it. In most proteins, the primary structure uniquely determines the 3-dimensional structure of a protein in its native environment. An exception is the misfolded prion protein involved in bovine spongiform encephalopathy. This structure is linked to the function of the protein. Additional structural information includes the secondary, tertiary and quaternary structure. A viable general solution to the prediction of the function of a protein remains an open problem. Most efforts have so far been directed towards heuristics that work most of the time.
== After Liberation == Smolková-Keulemansová suffered from dysentery, jaundice, typhus and tuberculosis after liberation. She could not give an address to anyone she knew in Prague, so the International Red Cross did not allow her to return to her country of origin. To receive medical treatment, she was selected to go to Sweden for a six-month recovery stay with 6,000 other prisoners.
Sources: en.wikipedia.org
In 1889, Joseph von Mering and Oskar Minkowski excised the pancreas of a dog, which soon developed the symptoms of diabetes. According to some accounts, Minkowski was taught by his supervisor, Bernhard Naunyn, to test for sugar in urine whenever he noticed polyuria. According to some other accounts, a laboratory attendant pointed out that only the urine of the pancreatectomized dogs attracted flies, prompting the researchers to test for sugar. Ultimately, the pair tested for sugar in the urine and confirmed the connection with diabetes mellitus. This event is commonly credited as the formal discovery of a role for the pancreas in diabetes. While the researchers continued to work on obtaining a pancreatic extract, they were unable to obtain the presumed anti-diabetic substance. In 1893, Edouard Hédon in Montpellier conducted a pancreatectomy in two stages. In the first, he took out almost all of the pancreas, cutting off the supply of pancreatic juice entirely. He then left a small remnant of pancreas grafted under the dog's skin. The dog did not become diabetic until the remaining graft was also excised, leading Hédon to the conclusion that the pancreas must have two functions: digestion via an external secretion, and carbohydrate metabolism via some internal secretion that was released directly into the bloodstream. John MacLeod, among the Toronto group that later isolated and purified insulin for clinical use, cited this finding as the most convincing proof of an internal secretion in his 1913 book, Diabetes: Its Pathological Physiology.
=== Iodine deficiency === Among humans with dietary iodine deficiency, the thyroid will not be able to make thyroid hormones. The lack of thyroid hormones will lead to decreased negative feedback on the pituitary gland, leading to increased production of thyroid-stimulating hormone, which causes the thyroid to enlarge in a medical condition called endemic colloid goitre. This has the effect of increasing the thyroid's ability to trap more iodide, compensating for the iodine deficiency and allowing it to produce adequate amounts of thyroid hormone.
=== Generic names === Metandienone is the generic name of the drug and its INNTooltip International Nonproprietary Name, while methandienone is its BANTooltip British Approved Name and métandiénone is its DCFTooltip Dénomination Commune Française. It is also referred to as methandrostenolone and as dehydromethyltestosterone. The former synonym should not be confused with methylandrostenolone, which is another name for a different AAS known as metenolone.
Sources: en.wikipedia.org
Pattern hair loss is classified as a form of noncicatricial alopecia, i.e. a sort of non-inflammatory non-scarring hair loss. Male-pattern hair loss begins above the temples and at the vertex (calvaria) of the scalp. As it progresses, a rim of hair at the sides and rear of the head remains. This has been referred to as a "Hippocratic wreath" and rarely progresses to complete baldness. Female-pattern hair loss more often causes diffuse thinning without hairline recession; similar to its male counterpart, female androgenic alopecia rarely leads to total hair loss. The Ludwig scale grades severity of female-pattern hair loss. These include Grades 1, 2, 3 of balding in women based on their scalp showing in the front due to thinning of hair. In most cases, receding hairline is the first starting point; the hairline starts moving backwards from the front of the head and the sides.
The development of necrotizing myopathy after statin exposure is insufficient to make the diagnosis. Testing must first exclude other causes of myositis and necrotizing myopathy. A muscle biopsy consistent with SAAM will demonstrate muscle cell death with muscle fiber regeneration and typically has few inflammatory cells. Immunohistochemistry testing may demonstrate additional pathologic features of SAAM. Such findings include the presence of endothelial cell membrane attack complex in non-necrotic muscle fibers and MHC class I expression. Antibodies against HMG-CoA reductase occur in 94% of affected individuals. These antibodies are known to also occur in people who do not take statin medications. Conversely, these antibodies are absent in people who take statin medications but do not have myopathy. Thus, the presence of anti-HMG CoA reductase antibodies in someone who uses a statin and has myopathy strongly supports the diagnosis. CK levels increase to 10-100 times above normal (2000–20,000 IU/L) in more than 90% of cases. Electromyography (EMG) typically demonstrates a myopathic pattern of findings. Muscle swelling may be seen on MRI imaging.
Graphite oxides absorb moisture in proportion to humidity and swell in liquid water. The amount of water absorbed by graphite oxides depends on the particular synthesis method and shows a strong temperature dependence. Brodie graphite oxide selectively absorbs methanol from water/methanol mixtures in a certain range of methanol concentrations. Membranes prepared from graphite oxides (recently more often called "graphene oxide" membranes) are vacuum tight and impermeable to nitrogen and oxygen, but are permeable to water vapors. The membranes are also impermeable to "substances of lower molecular weight". Permeation of graphite and graphene oxide membranes by polar solvents is possible due to swelling of the graphite oxide structure. The membranes in swelled state are also permeable by gases, e.g. helium. Graphene oxide sheets are chemically reactive in liquid water, leading them to acquire a small negative charge. The interlayer distance of dried graphite oxides was reported as ~6–7 Å but in liquid water it increases up to 11–13 Å at room temperature. The lattice expansion becomes stronger at lower temperatures. The inter-layer distance in diluted NaOH reached infinity, resulting in dispersion of graphite oxide into single-layered graphene oxide sheets in solution. Graphite oxide can be used as a cation exchange membrane for materials such as KCl, HCl, CaCl2, MgCl2, BaCl2 solutions. The membranes were permeable by large alkali ions as they are able to penetrate between graphene oxide layers.
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing laronidase (Aldurazyme, commercialized by Genzyme Corporation). BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU). Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials.
Sources: en.wikipedia.org
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.
No. The gastric protein is larger, while BPC-157 is a short fragment sequence. The peptide is produced synthetically for research use. The relationship is one of sequence origin, not chemical identity.
It is most often supplied as a lyophilized powder, frequently as the acetate salt. The powder is reconstituted with water or a buffer before use. Free-base and other salt forms also exist but are less common in catalogs.
The standard approach is reverse-phase high-performance liquid chromatography, reported as a percentage of total peak area. Because that figure alone says little about the nature of the impurities, the accompanying chromatogram is normally the more useful document for judging a batch.